（既出情報ですが、Vectura社 Latest newsより抜粋）
25 Jan 2017
Seebri® / Ultibro® Breezhaler® 2016 sales reach $512 million triggering $5 million milestone receipt
Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways disease, announces that a sales milestone receipt of $5 million has been triggered following confirmation by Novartis that EU/ROW combined net sales of Seebri® Breezhaler® and Ultibro® Breezhaler® for the year to 31 December 2016 have reached $512 million.
（既出情報ですが、Vectura社 Latest newsより抜粋）
25 Jan 2017
Seebri® / Ultibro® Breezhaler® 2016 sales reach $512 million triggering $5 million milestone receipt
Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways disease, announces that a sales milestone receipt of $5 million has been triggered following confirmation by Novartis that EU/ROW combined net sales of Seebri® Breezhaler® and Ultibro® Breezhaler® for the year to 31 December 2016 have reached $512 million.
（添付は、ノバルティス決算より抜粋）
MSしつこい一方、金男買い戻し加速、
今後も悪しき空売り機関の餌食にならぬよう、
ゆったりゆっくり着実に現物長期で。、
創薬力＆成長性に対する評価、注目度は青天井！！
グローバルバイオ企業への序章〜次なる大飛躍、
日本版ギリアドへ。
頑張れ、そーせい！！